EP1572247A1 - Radioablation von haemolymphopoietischen zellpopulationen - Google Patents
Radioablation von haemolymphopoietischen zellpopulationenInfo
- Publication number
- EP1572247A1 EP1572247A1 EP02808232A EP02808232A EP1572247A1 EP 1572247 A1 EP1572247 A1 EP 1572247A1 EP 02808232 A EP02808232 A EP 02808232A EP 02808232 A EP02808232 A EP 02808232A EP 1572247 A1 EP1572247 A1 EP 1572247A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- acid
- cells
- edtmp
- dotmp
- bone marrow
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000004027 cell Anatomy 0.000 claims abstract description 85
- 238000000034 method Methods 0.000 claims abstract description 66
- 210000001185 bone marrow Anatomy 0.000 claims abstract description 60
- 206010068051 Chimerism Diseases 0.000 claims abstract description 53
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 34
- 239000012217 radiopharmaceutical Substances 0.000 claims abstract description 27
- 229940121896 radiopharmaceutical Drugs 0.000 claims abstract description 27
- 230000002799 radiopharmaceutical effect Effects 0.000 claims abstract description 27
- 210000001519 tissue Anatomy 0.000 claims abstract description 25
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 20
- 210000000056 organ Anatomy 0.000 claims abstract description 20
- 210000004698 lymphocyte Anatomy 0.000 claims abstract description 16
- 230000004044 response Effects 0.000 claims abstract description 15
- 230000003247 decreasing effect Effects 0.000 claims abstract description 5
- 229940120146 EDTMP Drugs 0.000 claims description 62
- 238000002054 transplantation Methods 0.000 claims description 22
- 210000003491 skin Anatomy 0.000 claims description 19
- 239000002253 acid Substances 0.000 claims description 16
- 239000003446 ligand Substances 0.000 claims description 13
- 239000003607 modifier Substances 0.000 claims description 12
- 239000002243 precursor Substances 0.000 claims description 12
- NFDRPXJGHKJRLJ-UHFFFAOYSA-N edtmp Chemical compound OP(O)(=O)CN(CP(O)(O)=O)CCN(CP(O)(O)=O)CP(O)(O)=O NFDRPXJGHKJRLJ-UHFFFAOYSA-N 0.000 claims description 11
- 239000000427 antigen Substances 0.000 claims description 10
- 102000036639 antigens Human genes 0.000 claims description 10
- 108091007433 antigens Proteins 0.000 claims description 10
- KZUNJOHGWZRPMI-AKLPVKDBSA-N samarium-153 Chemical compound [153Sm] KZUNJOHGWZRPMI-AKLPVKDBSA-N 0.000 claims description 10
- 210000000130 stem cell Anatomy 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 8
- YDONNITUKPKTIG-UHFFFAOYSA-N [Nitrilotris(methylene)]trisphosphonic acid Chemical compound OP(O)(=O)CN(CP(O)(O)=O)CP(O)(O)=O YDONNITUKPKTIG-UHFFFAOYSA-N 0.000 claims description 8
- 229940090960 diethylenetriamine pentamethylene phosphonic acid Drugs 0.000 claims description 8
- DUYCTCQXNHFCSJ-UHFFFAOYSA-N dtpmp Chemical compound OP(=O)(O)CN(CP(O)(O)=O)CCN(CP(O)(=O)O)CCN(CP(O)(O)=O)CP(O)(O)=O DUYCTCQXNHFCSJ-UHFFFAOYSA-N 0.000 claims description 8
- XOHQAXXZXMHLPT-UHFFFAOYSA-N ethyl(phosphonooxy)phosphinic acid Chemical compound CCP(O)(=O)OP(O)(O)=O XOHQAXXZXMHLPT-UHFFFAOYSA-N 0.000 claims description 8
- MBKDYNNUVRNNRF-UHFFFAOYSA-N medronic acid Chemical compound OP(O)(=O)CP(O)(O)=O MBKDYNNUVRNNRF-UHFFFAOYSA-N 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 102100032937 CD40 ligand Human genes 0.000 claims description 6
- -1 Dy-165 Chemical compound 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- CIOAGBVUUVVLOB-OUBTZVSYSA-N strontium-89 Chemical compound [89Sr] CIOAGBVUUVVLOB-OUBTZVSYSA-N 0.000 claims description 6
- 102000004127 Cytokines Human genes 0.000 claims description 5
- 108090000695 Cytokines Proteins 0.000 claims description 5
- RCXMQNIDOFXYDO-UHFFFAOYSA-N [4,7,10-tris(phosphonomethyl)-1,4,7,10-tetrazacyclododec-1-yl]methylphosphonic acid Chemical compound OP(O)(=O)CN1CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CC1 RCXMQNIDOFXYDO-UHFFFAOYSA-N 0.000 claims description 5
- JKTORXLUQLQJCM-UHFFFAOYSA-N 4-phosphonobutylphosphonic acid Chemical compound OP(O)(=O)CCCCP(O)(O)=O JKTORXLUQLQJCM-UHFFFAOYSA-N 0.000 claims description 4
- 108010029697 CD40 Ligand Proteins 0.000 claims description 4
- 101150013553 CD40 gene Proteins 0.000 claims description 4
- 102100025680 Complement decay-accelerating factor Human genes 0.000 claims description 4
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 claims description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 4
- 102100022339 Integrin alpha-L Human genes 0.000 claims description 4
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 4
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 4
- 239000007983 Tris buffer Substances 0.000 claims description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 4
- 230000000961 alloantigen Effects 0.000 claims description 4
- IMUDHTPIFIBORV-UHFFFAOYSA-N aminoethylpiperazine Chemical compound NCCN1CCNCC1 IMUDHTPIFIBORV-UHFFFAOYSA-N 0.000 claims description 4
- 210000004204 blood vessel Anatomy 0.000 claims description 4
- 210000003890 endocrine cell Anatomy 0.000 claims description 4
- 210000003494 hepatocyte Anatomy 0.000 claims description 4
- 230000001900 immune effect Effects 0.000 claims description 4
- 239000003018 immunosuppressive agent Substances 0.000 claims description 4
- 229940124589 immunosuppressive drug Drugs 0.000 claims description 4
- 210000004153 islets of langerhan Anatomy 0.000 claims description 4
- 210000003061 neural cell Anatomy 0.000 claims description 4
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 229960003330 pentetic acid Drugs 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 210000004903 cardiac system Anatomy 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 210000002510 keratinocyte Anatomy 0.000 claims description 3
- 210000003205 muscle Anatomy 0.000 claims description 3
- 208000026872 Addison Disease Diseases 0.000 claims description 2
- 208000002017 Autoimmune Hypophysitis Diseases 0.000 claims description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 2
- 206010064539 Autoimmune myocarditis Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 claims description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 2
- 208000003807 Graves Disease Diseases 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 208000001204 Hashimoto Disease Diseases 0.000 claims description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 206010047112 Vasculitides Diseases 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 206010047642 Vitiligo Diseases 0.000 claims description 2
- 208000004631 alopecia areata Diseases 0.000 claims description 2
- 201000005000 autoimmune gastritis Diseases 0.000 claims description 2
- 208000010928 autoimmune thyroid disease Diseases 0.000 claims description 2
- 210000001196 cardiac muscle myoblast Anatomy 0.000 claims description 2
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 2
- 210000001612 chondrocyte Anatomy 0.000 claims description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 2
- 210000004087 cornea Anatomy 0.000 claims description 2
- 201000001981 dermatomyositis Diseases 0.000 claims description 2
- 230000002124 endocrine Effects 0.000 claims description 2
- 210000003372 endocrine gland Anatomy 0.000 claims description 2
- 210000002889 endothelial cell Anatomy 0.000 claims description 2
- 210000001508 eye Anatomy 0.000 claims description 2
- 210000005095 gastrointestinal system Anatomy 0.000 claims description 2
- 210000002216 heart Anatomy 0.000 claims description 2
- 210000000936 intestine Anatomy 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 210000000867 larynx Anatomy 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 210000002346 musculoskeletal system Anatomy 0.000 claims description 2
- 210000003098 myoblast Anatomy 0.000 claims description 2
- 210000000107 myocyte Anatomy 0.000 claims description 2
- 210000005036 nerve Anatomy 0.000 claims description 2
- 210000000653 nervous system Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 208000011610 primary hypophysitis Diseases 0.000 claims description 2
- 210000002345 respiratory system Anatomy 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 210000002229 urogenital system Anatomy 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 abstract description 7
- 230000005855 radiation Effects 0.000 abstract description 7
- 231100000433 cytotoxic Toxicity 0.000 abstract description 5
- 230000001472 cytotoxic effect Effects 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 69
- 241001465754 Metazoa Species 0.000 description 24
- 230000003750 conditioning effect Effects 0.000 description 19
- 230000000735 allogeneic effect Effects 0.000 description 18
- 230000006698 induction Effects 0.000 description 14
- 238000013459 approach Methods 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 230000001052 transient effect Effects 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 9
- 230000002285 radioactive effect Effects 0.000 description 9
- 238000010322 bone marrow transplantation Methods 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 8
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 210000003714 granulocyte Anatomy 0.000 description 7
- 230000007774 longterm Effects 0.000 description 6
- 231100001160 nonlethal Toxicity 0.000 description 6
- 210000004988 splenocyte Anatomy 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 5
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 5
- 238000011740 C57BL/6 mouse Methods 0.000 description 5
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical compound NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 230000024664 tolerance induction Effects 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- JSTADIGKFYFAIY-GJNDDOAHSA-K [2-[bis[[hydroxy(oxido)phosphoryl]methyl]amino]ethyl-(phosphonomethyl)amino]methyl-hydroxyphosphinate;samarium-153(3+) Chemical compound [H+].[H+].[H+].[H+].[H+].[153Sm+3].[O-]P([O-])(=O)CN(CP([O-])([O-])=O)CCN(CP([O-])([O-])=O)CP([O-])([O-])=O JSTADIGKFYFAIY-GJNDDOAHSA-K 0.000 description 4
- 210000001772 blood platelet Anatomy 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000002435 cytoreductive effect Effects 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 231100000518 lethal Toxicity 0.000 description 4
- 230000001665 lethal effect Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010062016 Immunosuppression Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000139 costimulatory effect Effects 0.000 description 3
- 230000003394 haemopoietic effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000011476 stem cell transplantation Methods 0.000 description 3
- 230000002992 thymic effect Effects 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 2
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 2
- 229910052772 Samarium Inorganic materials 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 230000001400 myeloablative effect Effects 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 229940051022 radioimmunoconjugate Drugs 0.000 description 2
- 229910052761 rare earth metal Inorganic materials 0.000 description 2
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000699679 Cricetulus migratorius Species 0.000 description 1
- 208000004332 Evans syndrome Diseases 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 208000031814 IgA Vasculitis Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000036631 Metastatic pain Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101001065556 Mus musculus Lymphocyte antigen 6G Proteins 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000004046 hyporesponsiveness Effects 0.000 description 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 108700043516 mouse H-2Kb Proteins 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 150000002910 rare earth metals Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- VIDRYROWYFWGSY-UHFFFAOYSA-N sotalol hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 VIDRYROWYFWGSY-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940006509 strontium-89 Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000155 toxicity by organ Toxicity 0.000 description 1
- 230000007675 toxicity by organ Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the invention relates to the use of bone agent radiopharmaceuticals, and more particularly those that target bone and can deliver a radiation dose to the bone marrow and bone marrow-derived cells so as to aid in inducing hemolymphopoietic chimerism.
- Manipulation of the human immune system has provided several challenges for the medical community, including providing therapies for the treatment of refractory autoimmune diseases, and providing tolerance to organ, tissue and cell transplants.
- Autoimmune diseases are those wherein a person's immune system mistakenly attacks the cells, tissues and organs of that person's own body.
- Treatment of refractory autoimmune diseases has been an elusive goal.
- Bone marrow transplantation is a commonly utilized procedure for the treatment of hematological disorders including malignancies, and has been recently proposed as a therapeutic option for refractory autoimmune diseases. See, for example, Saba N. et al., "Bone marrow transplantation for nonmalignant diseases",.
- Transplantation tolerance defined as complete acceptance of a graft or organ, tissue or cell transplant by an otherwise fully immunocompetent host without the need for long-term immunosuppression, has also been an elusive goal.
- both chronic and acute graft rejection are alleviated mainly by the use of non-specific immunosuppressive regimens that are often associated with severe complications including development of neoplasms and organ toxicity.
- CTLA4-Ig plus bone marrow induces long-term allograft survival and donor specific unresponsiveness in the murine model.
- U.S. Patent Nos. 5,514,364; 5,635,156; and 5,876,692 describe the use of cell type-specific antibodies directed to antigens localized on subsets of cells in combination with whole body radiation to enhance chimerism and to increase tolerance induction after donor bone marrow transplantation. These patents do not describe the use of non-immunological radioconjugated compounds, such as phosphonate compounds, for the induction of hemolymphopoietic chimerism.
- U.S. Patent No. 5,902,825 discloses therapeutic compositions containing an active agent complex formed of a non-radioactive metal ion and an organic phosphonic acid ligand, wherein the metal ion may be a Lanthanide.
- the '825 patent teaches that such compositions may be used in the treatment of bone diseases and in methods of reducing bone pain, but does not address issues related to bone marrow transplantation. In particular, no suggestion is made to therapeutically target bone marrow or bone marrow-derived cells to achieve chimerism via bone marrow or bone marrow- derived cell transplantation for the induction of tolerance to graft-related antigens.
- U.S. Patent No. 5,697,902 discloses therapeutic compositions and their methods of use in destroying bone-marrow cells in a patient prior to regrafting with normal bone marrow cells.
- the disclosed method comprises treating a patient with a cytotoxic amount of an antibody or antibody fragment specific to a marker associated with, or produced by, bone marrow cells and which is conjugated to a cytotoxic agent.
- suitable antibodies are described as being NP-2, MN3, and other antibodies that react with bone marrow cells, such as progenitor cell types.
- Radioisotopes preferred for therapeutic use with conjugated antibodies include 153 samarium.
- This patent discloses a protocol for infusion of autologous bone marrow, but does not address the issues concerning successful induction of transplantation tolerance for achieving hemolymphopoietic chimerism via bone marrow transplantation.
- U.S. Patent No. 6,241,961 discloses therapeutic radioimmunoconjugates for use in human therapy and methods for their production.
- radioimmunoconjugates may consist of a monoclonal antibody having binding specificity for CD 19, CD20, CD22, HLL2, HLA DRIO ⁇ , and CD66, conjugated to a radioisotope, and is useful in treating hemolymphopoietic diseases.
- the '961 patent does not suggest the use of non-antibody mediated targeting of bone marrow cells for chimerism induction via bone marrow or bone marrow-derived cell transplantation for tolerance to alloantigens,
- U.S. Patent No. 4,898,724 (hereinafter the '724 patent) teaches the use of Sm-153 with aminophosphonic acid chelators for the treatment of calcific tumors.
- Administration of chelates such as Sm-153-EDTMP is used to deliver a beta radiation dose to bone tumors.
- a dose to bone marrow occurs resulting in a transient bone marrow suppression.
- the '724 patent does not teach or suggest the use of such chelates for chimerism induction.
- U.S. Patent No. 4,882,142 (hereinafter the '142 patent) teaches the use of aminophosphonic acid complexes of radioactive rare earth metal ions such as Sm-153 and Ho-166 for the suppression of bone marrow.
- a preferred embodiment is the complex formed between the macrocyclic aminophosphonic acid DOTMP and the radioactive metal Ho-166. I.V. injections of these chelates resulted in accumulation of the radioactivity in bone with the effect of suppressing or ablating bone marrow.
- the ' 142 patent does not teach or suggest induction of chimerism.
- radioactive bone agents including ablation of the marrow, treating of calcific tumors, and treating autoimmune disease.
- this reference does not teach induction of chimerism. Rather, Fritzberg et. al propose the use of growth stimulating hormones that would speed up the recovery of bone marrow and as a result would not be conducive to the induction of chimerism..
- the present invention is a method of achieving hemolymphopoietic chimerism comprising administering to a recipient a bone seeking radiopharmaceutical; transplanting bone marrow or bone marrow-derived cells into the recipient; and transiently suppressing lymphocyte response so as to induce hemolymphopoietic chimerism.
- the present invention is a method for decreasing rejection of transplanted organs, tissues or cells comprising administering to a recipient a bone seeking radiopharmaceutical; transplanting bone marrow or bone marrow-derived cells into the recipient; transiently suppressing lymphocyte response; and transplanting one or more organs, tissues or cells.
- the present invention is a method to treat autoimmune disease comprising administering to a recipient a bone seeking radiopharmaceutical; transplanting bone marrow or bone marrow-derived cells into the recipient; and transiently suppressing lymphocyte response.
- the present invention has the advantage of inducing hemolymphopoietic chimerism without the need for lethal or sub-lethal conditioning regimens as used in some of the methods described in the above identified prior art.
- the use of bone-seeking radioactive compounds represents a viable approach to creating the "space" required for the donor stem cellengraftment and hemolymphopoietic chimerism without the need for external radiation or harsh cytotoxic drugs.
- the method of the present invention also provides more certainty that hemolymphopoietic chimerism will indeed result, as opposed to some of the methods of the prior art that do not provide an environment allowing induction of chimerism to an adequate degree. And, using the method of the present invention, tolerance to an organ, cell, or tissue transplant can be achieved.
- FIGURE 1 graphically depicts the results of treating mice with a single dose, IV, of 153 Sm- EDTMP, 150 ⁇ Ci or 500 ⁇ Ci, prior to administration of 20x10 6 or 100x10° allogeneic donor bone marrow-derived cells (BMC) as a single intravenous (TV) dose;
- FIGURE 2 graphically shows that a single administration of BMC resulted in bone marrow engraftment in all recipients analyzed
- FIGURE 3 graphically shows the percentage of donor-derived cells in recipients treated with 20x10 BMC, anti-CD 154 mAb, and one of 4 conditioning approaches;
- FIGURE 4 shows the percentage of donor-derived cells in control animals treated with 100x10° BMC and one of the 4 conditioning approaches
- FIGURE 5 shows the percentage of donor-derived cells in the control animals treated with 20x10 BMC, and one of the 4 conditioning approaches;
- FIGURE 6 shows the percent of donor-derived cells in the control animals treated with 20xl0 6 BMC or 100x10° BMC along with anti-CD154 mAb (in the absence of 153 Sm- EDTMP treatment);
- FIGURE 7 depicts a two-color flow cytometric analysis of the proportion of donor-derived lymphoid (B cells), NK, and myeloid (granulocytes) lineages in representative mixed chimeras prepared using a non-lethal conditioning regiment of 20x10 6 BMC, 153 Sm- EDTMP, and anti-CD154 mAb (upper panels) as well as 20x10° BMC and anti-CD154 mAb (lower panels);
- FIGURE 8 depicts a two-color flow cytometric analysis of the proportion of donor-derived lymphoid (B cells), NK, and myeloid (granulocytes) lineages in representative mixed chimeras prepared using a non-lethal conditioning regiment of 100x10° BMC, 153 Sm- EDTMP, and anti-CD 154 mAb (upper panels) as well as 100x10° BMC and anti-CD 154 mAb (lower panels);
- FIGURE 9 graphically shows the survival of full thickness tail-derived skin grafts placed on the recipients treated with 20x10 6 BMC, I53 Sm-EDTMP, and anti-CD 154 mAb, or the indicated control groups;
- FIGURE 10 graphically depict the survival of full thickness tail-derived skin grafts placed on the recipients treated with 100x10° BMC, 153 Sm-EDTMP, and anti-CD 154 mAb, or the indicated control groups.
- the present invention focuses on a novel approach of attaining a profound, but transient myelodepression by selectively targeting the recipient bone marrow in order to achieve multilineage chimerism.
- the present invention can be used to obtain multilineage hemolymphopoietic chimerism.
- multilineage is defined herein to mean that more than one cell lineage derived from bone marrow-contained precursors is detectable in the recipient.
- the present invention has particular applicability to inducing transplantation tolerance in a recipient of an organ, tissue or cell transplant, and to treating autoimmune diseases.
- hemolymphopoietic chimerism is induced so as to provide immunological tolerance to at least one member of the group consisting of alloantigens, autoantigens and xenoantigens.
- Alloantigens are those antigens recognized by the immune system that are expressed on cells, tissues or organs of a non-identical individual of the same species.
- Autoantigens are those antigens expressed by an individual's tissues, cells or organs that elicit an autoimmune response or that are the target of an autoimmune disease.
- Xenoantigens are those antigens recognized by the immune system that are expressed on cells, tissues or organs of an individual of a different species.
- the method of the present invention includes the step of administering a bone seeking radiopharmaceutical to a recipient.
- a bone seeking radiopharmaceutical is defined herein to mean a complex of a radionuclide and a ligand which targets bone rather than soft tissue.
- the radiopharmaceutical comprises a rare earth radionuclide complexed with an aminophosphonic acid.
- Preferred radionuclides include Sm-153, Ho-166, Gd-159, Lu-177, Dy-165, Y-90, In-155m, Re-186, Re-188, Sn-117m, La-140,I-131, Cu-67, Ac-225, Bi-212, Bi-213, At-211, Ra-223, Pm-149, Rh-105; Au-198, Au-199, Dy-166, Sc-47, Yb-175, P-32, Sr-89, Ir-192, Tb-149, and Ra-224.
- Preferred ligands include aminophosphonic acids and lower carboxylic acids. More preferably, the ligand is selected from the group consisting of ethylenediaminetetramethylenephosphonic acid (EDTMP), diethylenetriaminepentamethylenephosphonic acid (DTPMP), hydroxyethylethylenediaminetrimethylenephosphonic acid (HEEDTMP), nitrilotrimethylenephosphonic acid (NTMP), tris(2- aminoethyl)aminehexamethylenephosphonic acid (TTHMP), 1- carboxyethylenediaminetetramethylenephosphonic acid (CEDTMP) and bis(aminoethylpiperazine)tetramethylenephosphonic acid (AEPTMP),.
- ETMP ethylenediaminetetramethylenephosphonic acid
- DTPMP diethylenetriaminepentamethylenephosphonic acid
- HEDTMP hydroxyethylethylenediaminetrimethylenephosphonic acid
- NTMP nitrilotrimethylenephosphonic acid
- TTHMP tris(
- Ethylenediaminetetraacetic acid l,4,7,10-tetraazacyclododecane-N,N',N",N'"- tetramethylenephosphonic acid (DOTMP), hydroxyethyldiphosphonic acid (HEDP), methylenediphosphonic acid (MDP), diethylenetriaminepentaacetic acid (DTP A), hydroxethylethylenediaminetriacetic acid (HEDTA), and nitrilotriacetic acid (NTA).
- DOTMP Ethylenediaminetetraacetic acid
- HEDP hydroxyethyldiphosphonic acid
- MDP methylenediphosphonic acid
- DTP A diethylenetriaminepentaacetic acid
- HEDTA hydroxethylethylenediaminetriacetic acid
- NTA nitrilotriacetic acid
- the bone seeking radiopharmaceutical complex is chosen from the group consisting of Sm-153-EDTMP, Sm-153-DOTMP, Ho-166-EDTMP, Ho-166-DOTMP, Gd- 159-EDTMP, Gd-159-DOTMP, Dy-165-EDTMP, Dy-165-DOTMP, Re-186-HEDP, Re- 188-HEDP, and Sn-117m-DTPA.
- Certain bone seeking radiopharmaceuticals which can be used in the method of the present invention do not require the use of a chelating agent.
- P-32 can be used alone as a bone seeking radiopharmaceutical without a ligand.
- Sr-89 as the chloride can be used, as indicated in Robinson R G, Spicer J A, Preston D F, et al., "Treatment of Metastatic Bone Pain With Strontium-89,” Nucl. Med. Biol. 14:219-222 (1987).
- Preferred radiopharmaceuticals for use with the present invention include Sm-153-EDTMP, Sm-153- DOTMP, Ho-166-EDTMP, Ho-166-DOTMP, Gd-159-EDTMP, and Gd-159-DOTMP. Examples of these complexes are described in U.S Patents 4,976,950, 4,882,142, 5,059,412, 5,066,478, 5,064,633, 4,897,254, 4,898,724, and 5,300,279. More preferred radiopharmaceuticals for use with the present invention do not include Sm-153-EDTMP, but rather include complexes of Sm-153 with ligands other than EDTMP and complexes of EDTMP with radionuclides other than Sm-153. Most preferred radiopharmaceuticals include Sm-153-DOTMP, Ho-166-EDTMP, Ho-166-DOTMP, Gd-159-EDTMP, and Gd- 159-DOTMP.
- the bone seeking radiopharmaceutical may be introduced to a human bone marrow recipient in dosages ranging from 1 mCi/Kg to 50 mCi/Kg.
- the dose of the bone seeking radiopharmaceutical will depend upon the nuclear properties of the radionuclide, the localization of the radiopharmaceutical in bone, and the localization in other tissues. For example, an isotope with a long half life and a high energy emission would deliver a higher dose than one with a short half life and low energy emissions.
- a lower, diagnostic dose of the radiopharmaceutical may be used to determine the biodistribution of the bone seeking radiopharmaceutical allowing for an estimation of the dose prior to administration of the higher doses.
- a dose of from 3 miCi/Kg (111 MBq Kg) to 20 mCi/Kg (740 MBQ) is preferred. More preferred is a dose of 6 mCi/Kg (222 MBq/Kg) to 10 mCi/Kg (370 MBq/Kg) body weight.
- Each radionuclide and the form that it is administered will give a different dose. The dose is dependent on the decay properties of the radionuclide and the biodistribution.
- Preferred doses to the red bone marrow are from 800 rads (8 Grey) to 5,000 rads (50 Grey). More preferred is from 1600 Rads (16 Grey) to 3,000 rads (30 Grey).
- Radioactivity will remain in recipient bone, thereby affecting the bone marrow or bone marrow-derived cells therein, for the life of the isotope.
- Sm-153, Ho-166, and Gd-159 are preferred, other radioactive isotopes having relatively short, but clinically appropriate, half-lives may also be employed in complexes useful for the invention.
- Suitable complexes may be prepared according to known protocols optionally utilizing complex forming agents, or may be obtained from commercial sources.
- the radiopharmaceuticals may be formulated into any pharmaceutically acceptable dosage form, including liquids, emulsions, and suspensions. Liquid solutions for injection are particularly preferred. Pharmaceutical compositions of the complexes for use according to the invention may also contain suitable diluents, excipients, buffers, stabilizers and carriers. Sterile water or sterile isotonic saline solutions are particularly preferred. Another step in the method of the present invention entails transplanting the bone marrow- derived cells into a recipient.
- bone marrow-derived cells is defined herein to mean bone marrow cells, stem cells and precursors as well as cells obtained from the bone marrow and selected or manipulated in vitro (for example, cultured, enriched etc) as well as cells with stem cell/precursor cell properties obtained from other anatomical sources (peripheral blood after mobilization, cord blood etc). Bone marrow-derived cells are transplanted into the recipient via protocols known to those of skill in the art.
- the method of the present invention further comprises the step of transiently suppressing the lymphocyte response.
- Transient lymphocyte response suppression is defined to mean that the treatment is transient, or of a relatively short duration, as opposed to being chronic in duration.
- chronic lymphocyte response suppression is avoided with the use of the present invention, so as to minimize the side effects associated with such chronic lymphocyte suppression.
- a biological modifier is administered to the host.
- suitable biological modifiers include antibodies, cytokines, immunosuppressive drugs, peptides, proteins, nucleic acids or a combination thereof.
- the bone marrow-derived cells are transplanted in conjunction with at least one antibody raised against an antigen selected from the group consisting of CD4, CD8, CD3, CD5, CD55, CD40, CD40L, B7.1, B7.2, CD28, and LFA-1.
- Appropriate dosage levels and length of administration of the biological modifier can be determined by those of ordinary skill in the art and will depend upon factors such as histocompatability matching, dose of transplanted cells, age of the patient, and so forth.
- the method of the present invention is useful for decreasing rejection of transplanted organs, tissues or cells.
- the organs, tissues or cells can be transplanted using procedures known to those skilled in the art.
- Organs, tissues or cells for which transplantation tolerance can be enhanced by the present invention include liver, heart, lung, kidney, intestine, pancreas, larynx, blood vessels limbs, endocrine organs, skin, islet cells, cornea, nerves, muscles, keratinocytes and keratynocyte precursors , chondrocytes and condrocyte precursors hepatocytes and hepatocyte precursors, myocytes and myoblasts including cardiomyocytes and cardiomyoblasts, neural cells and neural cell precursors, endothelial cells, endocrine cells and endocrine cell precursors, stem cells and cells of different lineage derived from stem cells.
- the method of the present invention can be used to treat autoimmune disease.
- the bone marrow- derived cells that are transplanted during the bone marrow-derived cell transplantation step can be autologous or homologous.
- the bone marrow-derived cells can be either unmanipulated or depleted of mature T-lymphocytes prior to transplantation.
- autoimmune diseases typically affect the nervous system, cardiac system, the eye, cardiac system, respiratory system, urogenital system, gastrointestinal system, blood, blood vessels, endocrine glands, skin, and musculoskeletal system, including connective tissue diseases.
- the autoimmune diseases that can be treated using the method of the present invention include rheumatoid arthritis, ankylosing spondilytis polymyositis and dermatomyositis systemic lupus erythematosus, vasculitides, Goodpasture's syndrome Wegener granulomatosis uveitis Sjogren's syndrome Bechet's disease, autoimmune myocarditis and perycarditis, multiple sclerosis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, autoimmune gastritis, autoimmune hepatitis primary biliary chirrosis, diabetes, autoimmune thyroid disease Graves disease, Hashimoto thyroiditis, Addison's disease, ipoparat
- mice All animal procedures were performed under the supervision and approval of the University of Miami Institutional Animal Care and Use Committee (IACUC). Mice (7-8 week old Balb/c (H-2 d ), C57BL/6 (B6; H-2 b ) and C3H/HeJ (C3H; H-2 k )) were purchased from Jackson Laboratories (Bar Harbor, Maine). Recipient C57BL/6 mice were used at 9- 10 weeks of age. All animals were housed in pathogen-free room in sterile microisolator cages with autoclaved feed and autoclaved acidified water.
- IACUC University of Miami Institutional Animal Care and Use Committee
- Bone marrow-derived Cell Transplantation Balb/c mice, 8-9 weeks old, used as donors, were sacrificed on the day of the transplant.
- Bone marrow cells were prepared according to a previously published regimen. Briefly, after removing femura and tibiae, and cleaning them from muscle tissue and cartilage, BMC were flushed with sterile RPMI-1640 (Mediatech, Inc, Herndon, Virginia) supplemented with 0.8 mg/ml Gentamycin (Gibco, Gaithersburg, Maryland), using 23G needle. BMC were filtered through a sterile nylon mesh and counted.
- the grafts were first inspected on the eighth-day following grafting, and every third day thereafter. Graft rejection was considered complete when no viable graft tissue was detected by visual inspection. Recipient mice were considered to be tolerant when donor- specific skin grafts survived in perfect condition for ⁇ 150 days.
- Cells were also assessed for non-specific staining using an Ig isotype control (FITC-conjugated mouse IgG 2a and Cy-Chrome-conjugated rat IgG 2b ), and the percentage of cells stained with this Ab was subtracted from the values obtained from staining with the specific Ab to determine the relative number of positive cells. Reconstitution of various cell lineages was assessed using FITC-conjugated anti-mouse H- 2K b or H-2K d and PE-conjugated anti-mouse CD19/CD22 in the B cell, PE-conjugated anti- mouse Ly-6G in the granulocyte, and PE-conjugated anti-mouse Mac-3 in the macrophage compartments.
- Ig isotype control FITC-conjugated mouse IgG 2a and Cy-Chrome-conjugated rat IgG 2b
- Reconstitution of various cell lineages was assessed using FITC-conjugated anti-mouse H- 2K
- Recipient animals were first tested 1 week after BMC-Tx, every 2 weeks up to 6 weeks, and every 4 weeks thereafter.
- Purified anti-mouse CD16/CD32 (Fc ⁇ III/II) was used to block non-specific binding to the Fc receptors.
- FCM analyses were preformed using Cell Quest software on a FACScan cytometer purchased from Becton Dickinson & Co. (Mountain View, California).
- Splenocytes were used to analyze the expression of Vb3 + , Vb5 + , Vbl 1 + and Vbl4 + families in the chimeras at the time of sacrifice.
- cells were blocked with purified anti-mouse CD16/CD32 (Fc ⁇ III/II) (PharMingen), and then incubated with FITC-conjugated H-2K d and PE- conjugated anti-Vb3 + , Vb5 + , Vbl 1 + or Vbl4 + (PharMingen) for 30 minutes on ice.
- FITC- conjugated mouse IgG2a, PE-conjugated Armenian Hamster IgG, group 2, mouse IgGl, rat IgG2b and rat IgM antibodies were used as negative controls.
- Splenocytes depleted of red blood cells were incubated at 37°C in 5 percent CO for 3 days in quintuplicate wells containing 2 x 10 5 responders with 2 x 10 5 stimulators treated with Mytomicin C (Sigma, St. Louis, Missouri) in Iscove's tissue culture media (Gibco, Gaithersburgh, Maryland) containing 10 percent heat-inactivated FCS, 2 mM L-Glutamine (Mediatech), 25mM HEPES (Mediatech) and 0.05 mM ⁇ - mercaptoethanol.
- splenocytes isolated from na ⁇ ve Balb/c donors were incubated with several different dilutions (1 :3; 1: 10; 1:30; 1: 100) of plasma from the chimeric recipients at 4°C for 60 minutes.
- Cells were washed with PBS supplemented with 1 percent BSA, 0.02 percent sodium azide, and then incubated with FITC-conjugated goat anti-mouse IgG (H+L) (Jackson ImmunoResearch Laboratories, West Grove, Pennsylvania) and PE-conjugated anti-mouse CD22 for 30 minutes on ice.
- the cells were then washed with PBS and analyzed on a Becton Dickinson F AC Scan. Plasma from a na ⁇ ve C57BL/6 incubated with splenocytes from na ⁇ ve Balb/c donors was used as a baseline.
- Recipient animals C57BL/6, H-2 b
- BMC allogenic donor bone marrow cells
- BMC transplantation BMC-Tx
- MR-1 hamster anti-murine CD154 mAb
- the lower dose of 153 Sm, 150 ⁇ Ci proved to be as effective as the higher dose, 500 ⁇ Ci.
- Treatment with 153 Sm- EDTMP resulted in transient myelodepression that occurred one week post administration of the compound and was spontaneously resolved by 4-6 weeks post-administration, as shown in FIGURE 1.
- Both the 150 ⁇ Ci and 500 ⁇ Ci doses of 153 Sm-EDTMP have similar effect on hemolymphopoietic elements.
- WBC white blood cell counts
- administration of 153 Sm-EDTMP does not have significant effect on red blood cell (RBC), hemoglobin (Hb), and Platelet (PLT) counts.
- FIGURE 2 shows percentages of donor-derived cells in the recipients treated with lOOxlO 6 BMC, anti-CD 154 mAb, and one of 4 conditioning approaches- 153 Sm-EDTMP 150 ⁇ Ci, followed by administration of BMC on day 7; 153 Sm-EDTMP 500 ⁇ Ci, followed by administration of BMC on day 7, Sm-EDTMP 150 ⁇ Ci, followed by administration of BMC on day 14; and 153 Sm-EDTMP 500 ⁇ Ci, followed by administration of BMC on day 14.
- FIGURE 3 is shown the percentage of donor-derived cells in the recipients treated with 20x10 6 BMC, anti-CD 154 mAb, and one of the 4 conditioning approaches: 153 Sm-EDTMP 150 ⁇ Ci, followed by administration of BMC on day 7; 153 Sm-EDTMP 500 ⁇ Ci, followed by administration of BMC on day 7; I53 Sm-EDTMP 150 ⁇ Ci, followed by administration of BMC on day 14; and 153 Sm-EDTMP 500 ⁇ Ci, followed by administration of BMC on day
- the conditioning regimens were 153 Sm-EDTMP 150 ⁇ Ci, followed by administration of BMC on day 7; 153 Sm-EDTMP 500 ⁇ Ci, followed by administration of BMC on day 7; 153 Sm- EDTMP 150 ⁇ Ci, followed by administration of BMC on day 14; and 153 Sm-EDTMP 500 ⁇ Ci, followed by administration of BMC on day 14.
- This fourth regimen differs from the previous, since no anti-CD 154 mAb to induce costimulatory blockade was used.
- FIGURE 5 shows the percent of donor-derived cells in the control animals treated with 20x10 6 BMC, and one of the 4 conditioning approaches: 153 Sm-EDTMP 150 ⁇ Ci, followed by administration of BMC on day 7; 153 Sm-EDTMP 500 ⁇ Ci, followed by administration of BMC on day 7; 153 Sm-EDTMP 150 ⁇ Ci, followed by administration of BMC on day 14; and 153 Sm-EDTMP 500 ⁇ Ci, followed by administration of BMC on day 14 (this regimen differs from the previous, since no anti-CD 154 mAb to induce costimulatory blockade was used).
- the percentage of donor-derived cells in the control animals treated with 20x10 6 BMC or 100x10° BMC along with anti-CD154 mAb is shown in FIGURE 6.
- FIGURE 7 shows a two-color flow cytometric analysis of the proportion of donor-derived lymphoid (B cells), NK, and myeloid (granulocytes) lineages in representative mixed chimeras prepared using a non-lethal conditioning regiment of 20x10 BMC, Sm- EDTMP, and anti-CD 154 mAb (upper panels) as well as 20x10 6 BMC and anti-CD 154 mAb (lower panels). Analysis was performed using Class I H-2 d -FITC and either CD22 (B cells), NK, or GRAN1 (granulocytes), all PE. Analysis was performed on the lymphoid gate, and the values were normalized to 100 percent.
- FIGURE 8 is shown a two-color flow cytometric analysis of the proportion of donor- derived lymphoid (B cells), NK, and myeloid (granulocytes) lineages in representative mixed chimeras prepared using a non-lethal conditioning regiment of 100 10 BMC, Sm- EDTMP, and anti-CD 154 mAb (upper panels) as well as 100x10° BMC and anti-CD 154 mAb (lower panels). Analysis was preformed using Class I H-2 d -FITC and either CD22 (B cells), NK, or GRAN1 (granulocytes), all PE. Analysis was performed on the lymphoid gate, and the values were normalized to 100 percent.
- FIGURE 9 The survival of full thickness tail-derived skin grafts placed on the recipients treated with 20xl0 6 BMC, 153 Sm-EDTMP, and anti-CD154 mAb, or indicated control groups is shown in FIGURE 9. Grafts were prepared 30 days following the last administration of anti- CD154 mAb in the treated animals. Two different donor strain combinations, BALB/c (H- 2 d ) and C3H/J (H-2 k ) were used. Each recipient received skin grafts from both strains: donor-type, BALB/c (H-2 d ), as well as third-party, C3H/J (H-2 k ). Third party grafts were rejected within the same time frame as were donor-specific grafts placed on na ⁇ ve recipients.
- FIGURE 10 The survival of full thickness tail-derived skin grafts placed on the recipients treated with 100x10° BMC, 153 Sm-EDTMP, and anti-CD 154 mAb, or indicated control groups is depicted graphically in FIGURE 10. Grafts were prepared 30 days following the last administration of anti-CD 154 mAb in the treated animals. Two different donor strain combinations, BALB/c (H-2 d ) and C3H/J (H-2 k ) were used. Each recipient received skin grafts from both strains: donor-type, BALB/c (H-2 d ), as well as third-party, C3H/J (H-2 k ).
- allogeneic bone marrow-derived cells may be infused in the presence of a transient T cell co-stimulatory blockade obtained by administration of anti-CD 154 monoclonal antibodies (mAb).
- mAb monoclonal antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2002/039595 WO2004052408A1 (en) | 2002-12-10 | 2002-12-10 | Radioablation of hemolymphopoietic cell populations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1572247A1 true EP1572247A1 (de) | 2005-09-14 |
Family
ID=32505175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP02808232A Withdrawn EP1572247A1 (de) | 2002-12-10 | 2002-12-10 | Radioablation von haemolymphopoietischen zellpopulationen |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1572247A1 (de) |
| JP (1) | JP2006514020A (de) |
| AU (1) | AU2002368450A1 (de) |
| CA (1) | CA2509328A1 (de) |
| WO (1) | WO2004052408A1 (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102006599B1 (ko) | 2011-12-21 | 2019-08-01 | 아이소테라퓨틱스 그룹 엘엘씨 | 방사성 조성물 및 그의 치료적 사용 방법 |
| JP2016520650A (ja) * | 2013-06-05 | 2016-07-14 | アール−エヌエーヴィ・エルエルシー | スズ−１１７ｍでの免疫性、炎症性及び変形性関節炎の治療 |
| KR20180115979A (ko) * | 2017-04-14 | 2018-10-24 | 연세대학교 산학협력단 | 비스포스포네이트를 포함하는 만성 이식신 기능부전 예방 또는 치료용 조성물 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4882142A (en) * | 1988-12-19 | 1989-11-21 | The Dow Chemical Company | Bone marrow suppressing agents |
| US5635156A (en) * | 1993-09-13 | 1997-06-03 | University Of Pittsburgh | Non-lethal methods for conditioning a recipient for bone marrow transplantation |
| JP2003501488A (ja) * | 1999-06-11 | 2003-01-14 | ネオルックス コーポレイション | 骨髄抑制のための高投与量放射性核種錯体 |
-
2002
- 2002-12-10 CA CA002509328A patent/CA2509328A1/en not_active Abandoned
- 2002-12-10 EP EP02808232A patent/EP1572247A1/de not_active Withdrawn
- 2002-12-10 AU AU2002368450A patent/AU2002368450A1/en not_active Abandoned
- 2002-12-10 WO PCT/US2002/039595 patent/WO2004052408A1/en not_active Ceased
- 2002-12-10 JP JP2004559005A patent/JP2006514020A/ja active Pending
Non-Patent Citations (1)
| Title |
|---|
| See references of WO2004052408A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004052408A1 (en) | 2004-06-24 |
| JP2006514020A (ja) | 2006-04-27 |
| AU2002368450A1 (en) | 2004-06-30 |
| CA2509328A1 (en) | 2004-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2371728C (en) | High dose radionuclide complexes for bone marrow suppression | |
| US4882142A (en) | Bone marrow suppressing agents | |
| US7691985B2 (en) | Skeletal-targeted radiation to treat bone-associated pathologies | |
| Sykes et al. | Mixed chimerism | |
| US4976950A (en) | Bone marrow suppressing agents | |
| EP3700581A1 (de) | Anti-cd45-basierte konditionierungsverfahren und verwendungen davon in verbindung mit geneditierten zellbasierten therapien | |
| US20030228256A1 (en) | Methods of achieving transplantation tolerance through radioablation of hemolymphopoietic cell populations | |
| US4853209A (en) | Bone marrow suppressing agents | |
| WO2004052408A1 (en) | Radioablation of hemolymphopoietic cell populations | |
| WO2002040640A2 (en) | Methods of using cd8+/tcr- facilitating cells (fc) for the engraftment of purified hematopoietic stem cells (hsc) | |
| US20030003051A1 (en) | Methods of achieving transplantation tolerance through radioablation of hemolymphopoietic cell populations | |
| US20040228845A1 (en) | Methods of using CD8+/TCR- facilitating cells (FC) for the engraftment of purified hematopoietic stem cells (HSC) | |
| PARENTEAU et al. | Prolongation of graft survival in primate allograft transplantation by yttrium-90-labeled anti-Tac in conjunction with granulocyte colony-stimulating factor | |
| Prigozhina et al. | Depletion of alloantigen-primed lymphocytes overcomes resistance to allogeneic bone marrow in mildly conditioned recipients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20050711 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO |
|
| DAX | Request for extension of the european patent (deleted) | ||
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: STRICKLAND, ALAN, D. Inventor name: SIMON, JAIME Inventor name: SERAFINI, ALDO, N. Inventor name: PAGANELLI, GIOVANNIISTITUTO EUROPEO DI ONCOLOGIA Inventor name: RICORDI, CAMILLO Inventor name: INVERARDI, LUCA, A. |
|
| 17Q | First examination report despatched |
Effective date: 20070118 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20070530 |